Using an in vitro binding-site selection assay, we have demonstrated t
hat c-Myc-Max complexes bind not only to canonical CACGTG or CATGTG mo
tifs that are flanked by variable sequences but also to noncanonical s
ites that consist of an internal CG or TG dinucleotide in the context
of particular variations in the CA--TG consensus. None of the selected
sites contain an internal TA dinucleotide, suggesting that Myc protei
ns necessarily bind asymmetrically in the context of a CAT half-site.
The noncanonical sites can all be bound by proteins of the Myc-Max fam
ily but not necessarily by the related CACGTG- and CATGTG-binding prot
eins USF and TFE3. Substitution of an arginine that is conserved in th
ese proteins into MyoD (MyoD-R) changes its binding specificity so tha
t it recognizes CACGTG instead of the MyoD cognate sequence (CAGCTG).
However, like USF and TFE3, MyoD-R does not bind to all of the noncano
nical c-Myc-Max sites. Although this R substitution changes the intern
al dinucleotide specificity of MyoD, it does not significantly alter i
ts wild-type binding sequence preferences at positions outside of the
CA--TG motif, suggesting that it does not dramatically change other im
portant amino acid-DNA contacts; this observation has important implic
ations for models of basic-helix-loop-helix protein-DNA binding.